Matrix metalloproteinase-2 (MMP-2) is associated with the risk for a relapse in postmenopausal patients with node-positive breast carcinoma treated with antiestrogen adjuvant therapy

Breast Cancer Research and Treatment

Volumn 65, Issue 1, 2001, Pages 55-61

  Talvensaari Mattila, A ^a   Paakko P ^a   Blanco Sequeiros, G ^a   Turpeenniemi Hujanen, T ^a  

^a UNIVERSITY OF OULU   (Finland)

Author keywords

Breast cancer; Gelatinase A; Prognosis; Prognostic factor; Survival; Type IV collagenase

Indexed keywords

ANTIESTROGEN; ESTROGEN RECEPTOR; GELATINASE A; PROGESTERONE RECEPTOR; TAMOXIFEN; TOREMIFENE;

ADULT; ARTICLE; BREAST CARCINOMA; BREAST DISEASE; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR;

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CARCINOMA; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MATRIX METALLOPROTEINASE 2; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; POSTMENOPAUSE; PROGNOSIS; PROSPECTIVE STUDIES; RISK FACTORS; TAMOXIFEN; TOREMIFENE;

EID: 0035119039     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006458601568     Document Type: Article

References (29)

1. Cancer patients survival: Surveillance, epidemiology, and end results
2. Tumor size and axillary metastasis, a correlative occurence in 1244 cases of breast cancer between 1980 and 1995
3. Metastatic potential correlates with enzymatic degradation of basement membrane collagen
4. Expression of collagenase IV (basement membrane collagenase) activity in murine tumor cell hybrids which differ in metastatic potential
5. Degradation of basement membrane type IV collagen and lung subendothelial matrix by rat mammary adenocarcinoma cell clones of differing metastatic potentials
6. Prognostic value of MMP-2 immunoreactive protein (72 kD type IV collagenase) in primary skin melanoma
7. Expression of MMP (gelatinase) in T1 adenocarcinoma of the lung
8. Immunohistochemical distribution of type IV collagenase in normal, benign, and malignant breast tissue
9. Activity of type IV collagenases in benign and malignant breast disease
10. Type IV collagenases in invasive tumours
11. Laminin receptors, collagenase IV and prognosis in node-negative breast cancers
12. Immunohistochemical localization of matrix metalloproteinase 2 and its specific inhibitor TIMP-2 in neoplastic tissue with monoclonal antibodies
13. Relationship between matrix metalloproteinase expression and tumor angiogenesis in human breast carcinoma
14. Matrix metalloproteinase-2 immunoreactive protein, a marker of aggressiveness in breast carcinoma
15. Histological grading and prognosis in breast cancer
16. The use of avidin-biotinperoxidase complex (ABC) in immunoperoxidase technique: A comparison between ABC and unlabeled antibody (PAP) procedures
17. Urinary type IV collagenase elevated levels are associated with bladder transitional cell carcinoma
18. Matrix metalloproteinase-2 (72 kD type IV collagenase) expression occurs in the early stage of human melanocytic tumour progression and may have prognostic value
19. Nonparametric estimation from incomplete observations
20. Evaluation of survival data and two new rank order statistics arising in this consideration
21. A compertzian model of human breast cancer growth
22. Augmentation of type IV collagenase, laminin receptor, and Ki67 proliferation antigen associated with human colon, gastric, and breast carcinoma progression
23. Evaluation of basement membrane components and the 72 KDa type IV collagenase in serous tumours of the ovary
24. Enhanced expression of tissue inhibitor of metalloproteinase-2 (TIMP-2) in stroma of breast carcinomas correlates with tumour recurrence
25. Expression and tissue localization of membrane-types 1, 2, and 3 matrix metalloproteinases in human invasive breast carcinomas
26. 72 KD and 92 KD type IV collagenase, type IV collagen, and laminin mRNAs in breast cancer: A study by in situ hybridization
27. Matrix metalloproteinase-2 (MMP-2) immunoreactive protein - A new prognostic marker in uveal melanoma?